| I-01 Martina Liebich Modelling of Dexamethasone in Paediatric Leukaemia Patients using a Population Pharmacokinetic Approach Wednesday 10:30-12:00 |
| I-29 Thu Thuy Nguyen Population pharmacodynamic model of bronchodilator response to salbutamol in wheezy preschool children Wednesday 10:30-12:00 |
| I-34 Olafuyi Olusola The Use of Physiologically Based Pharmacokinetic Modelling in Assessing Drug–drug Interactions Associated with Antimalarial Treatment in Paediatrics Co-infected with Tuberculosis: A Case Study with Lumefantrine and Rifampicin. Wednesday 10:30-12:00 |
| I-37 Maria Panselina Dose-saturable model for amoxicillin used to predict probability of response in normal and obese pediatrics Wednesday 10:30-12:00 |
| I-58 Didier Renard Label extension for canakinumab in Adult Onset Still’s Disease (AOSD) – Extrapolation from pediatrics to adults Wednesday 10:30-12:00 |
| I-60 Christelle Rodrigues Population pharmacokinetics of the sustained-release granule formulation of valproic acid in epileptic children Wednesday 10:30-12:00 |
| I-70 Stein Schalkwijk Placental Transfer of Darunavir and Simulation of Fetal Exposure Wednesday 10:30-12:00 |
| II-14 Giovanni Smania The role of modelling and simulation in the paediatric investigation plan of a xanthine oxidase inhibitor for tumor lysis syndrome prevention Wednesday 15:10-16:30 |
| II-27 Tjokosela Tikiso Population Pharmacokinetics of Abacavir in HIV-infected African children Wednesday 15:10-16:30 |
| II-31 Alexios Tsiligiannis Optimization of a paediatric FDC tablet and dosing regimen for the first line treatment of tuberculosis. Wednesday 15:10-16:30 |
| II-47 Swantje Völler Normalisation weight in a covariate function affects the relative standard error of clearance: an example with paediatric data Wednesday 15:10-16:30 |
| II-51 Sebastian Weber Bayesian Pharmacokinetic Extrapolation from Dense Adult to Sparse Pediatric Data Wednesday 15:10-16:30 |
| II-56 Mélanie Wilbaux Effects of Formula Milk on Weight Changes in Healthy Term and Preterm Neonates Wednesday 15:10-16:30 |
| III-02 Esther Encinas Application of modelling and simulation (M&S) methods within the context of a paediatric-use marketing authorisation (PUMA) application Thursday 09:50-11:20 |
| III-08 Aline Fuchs Minimization of a utility function for optimizing the dosing frequency of amoxicillin administration in neonates according to a fixed PK/PD index Thursday 09:50-11:20 |
| III-09 Saskia Fuhrmann Model-based comparison of mAb clearance in pediatric populations* Thursday 09:50-11:20 |
| III-18 Sungwoo Goo Population pharmacokinetics(PK)/Pharmacodynamics(PD) modeling and simulation of vancomycin in pediatric infectious patients Thursday 09:50-11:20 |
| III-19 Verena Gotta Conceptual evaluation of urea rebound in pediatric hemodialysis patients by a physiology-based pharmacokinetic simulation study Thursday 09:50-11:20 |
| III-30 Paul Healy Impact of metabolic polymorphism on the exposure to tramadol and its active metabolite in children Thursday 09:50-11:20 |
| III-52 Frank Kloprogge Pharmacodynamics of vancomycin in children Thursday 09:50-11:20 |
| III-53 Ben Kluender Pharmacokinetic and Exposure-Response Analyses for Extrapolation of Efficacy of Adalimumab in Adolescent Patients with Hidradenitis Suppurativa Thursday 09:50-11:20 |
| III-56 Gilbert Koch Characterization of heart rate and sleeping patterns in pre-term neonates Thursday 09:50-11:20 |
| III-62 Christian Laveille Population pharmacokinetics of Rimeporide: a sodium-hydrogen exchanger (NHE-1) inhibitor for patients with Duchenne Muscular Dystrophy (DMD) Thursday 09:50-11:20 |
| IV-05 Louise Andrews New population pharmacokinetic model that predicts the individual starting dose of tacrolimus following pediatric renal transplantation Thursday 14:45-16:15 |
| IV-32 Elisa Calvier Accuracy of plasma clearance scaling from adults to children using pathway-specific covariate models: a systematic investigation using a physiologically-based pharmacokinetic workflow Thursday 14:45-16:15 |
| IV-36 Anne Chain An Extrapolation Approach to Aprepitant Pediatric Drug Development Thursday 14:45-16:15 |
| IV-45 Palang Chotsiri Population pharmacokinetic and time-to-event modelling of the antimalarial drug lumefantrine in young children with severe acute malnutrition Thursday 14:45-16:15 |
| IV-49 Sinziana Cristea The impact of renal transporters on paediatric renal clearance Thursday 14:45-16:15 |
